- Date 11 June 2025
- Documents : 2
- History
- (Restricted access link)
Listen
VYLOY (zolbétuximab) - Gastric or gastro-oesophageal junction adenocarcinomas
Opinions on drugs -
Posted on
Jun 18 2025
Reason for request
Inclusion on list
Summary of opinion
Favourable opinion for reimbursement in the MA indication.
No clinical added value of the new form compared to the forms already available.
Clinical Benefit
| Substantial |
The clinical benefit of VYLOY (zolbetuximab) 300 mg powder for concentrate for solution for infusion is substantial in the MA indication.
|
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
